Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. [electronic resource]
Producer: 20171107Description: 1217-1225 p. digitalISSN:- 1463-1326
- Aged
- Bile Acids and Salts -- metabolism
- Blood Glucose -- metabolism
- Chenodeoxycholic Acid -- metabolism
- Cholic Acid -- metabolism
- Deoxycholic Acid -- metabolism
- Diabetes Mellitus, Type 2 -- drug therapy
- Dipeptidyl-Peptidase IV Inhibitors -- therapeutic use
- Double-Blind Method
- Drug Therapy, Combination
- Fasting
- Feces -- chemistry
- Female
- Gallbladder -- diagnostic imaging
- Glycated Hemoglobin -- metabolism
- Humans
- Hypoglycemic Agents -- therapeutic use
- Liraglutide -- therapeutic use
- Male
- Metformin -- therapeutic use
- Middle Aged
- Organ Size
- Postprandial Period
- Sitagliptin Phosphate -- therapeutic use
- Sulfonylurea Compounds -- therapeutic use
- Ultrasonography
- Ursodeoxycholic Acid -- metabolism
- Glucagon-Like Peptide-1 Receptor Agonists
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.